Home / Market News / $LSTA
benzinga Corporate Catalyst Impact 65/100 ● positive

Lisata’s Marea Therapeutics Announces First Patient Dosed In Its Phase 2 Clinical Trial Of MAR002 For Treatment Of Acromegaly

Oct 5, 2026, 12:07 PM UTC · Primary ticker $LSTA

Lisata Therapeutics' subsidiary, Marea Therapeutics, announced the dosing of the first patient in its Phase 2 clinical trial for MAR002, a potential treatment for acromegaly. This marks a significant step in the drug's development, building on promising Phase 1 results that showed deep and durable IGF-1 suppression with a potentially less frequent dosing schedule than current standard of care.

Lisata Therapeutics, through its subsidiary Marea Therapeutics, has initiated a Phase 2 clinical trial for MAR002, an investigational therapy for acromegaly. This is a crucial milestone in the drug development process, as successful Phase 2 results can significantly de-risk the asset and pave the way for larger, more expensive Phase 3 trials. The filing highlights the potential for MAR002 to offer a more convenient dosing schedule (once every two weeks) compared to the daily injections of the current standard of care, which could be a significant competitive advantage. For traders, this represents a long-term opportunity for LSTA, as positive trial data could lead to substantial value creation. However, the short-term impact might be moderate as Phase 2 trials are still early stages, and success is not guaranteed. The key risk is the potential for the trial to fail or show insufficient efficacy/safety.

$LSTA positive Advancement of key pipeline asset
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.